Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.

Delgado-Calle J, Hancock B, Likine EF, Sato AY, McAndrews K, Sanudo C, Bruzzaniti A, Riancho JA, Tonra JR, Bellido T.

FASEB J. 2018 May;32(5):2878-2890. doi: 10.1096/fj.201700919RRR. Epub 2018 Jan 17.

PMID:
29401593
2.

ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.

Weiss JM, Chen W, Nyuydzefe MS, Trzeciak A, Flynn R, Tonra JR, Marusic S, Blazar BR, Waksal SD, Zanin-Zhorov A.

Sci Signal. 2016 Jul 19;9(437):ra73. doi: 10.1126/scisignal.aad8953.

3.

Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.

Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J, Lucas S, Koslow M, Roche M, Schueller O, Weiss S, Poyurovsky MV, Tonra J, Hippen KL, Dustin ML, Blazar BR, Liu CJ, Waksal SD.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9. doi: 10.1073/pnas.1414189111. Epub 2014 Nov 10.

4.

Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.

Samakoglu S, Deevi DS, Li H, Wang S, Murphy M, Bao C, Bassi R, Prewett M, Tonra JR.

Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):77-92.

PMID:
22399498
5.

Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.

Prewett M, Bassi R, Paz K, Amatulli M, Deevi D, Li H, Wang S, Witte L, Samakoglu S, Tonra JR.

Anticancer Res. 2011 Jun;31(6):2149-60.

PMID:
21737635
6.

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.

Duignan IJ, Corcoran E, Pennello A, Plym MJ, Amatulli M, Claros N, Iacolina M, Youssoufian H, Witte L, Samakoglu S, Schwartz J, Surguladze D, Tonra JR.

Neoplasia. 2011 Jan;13(1):49-59.

7.

Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor.

Tuma MC, Malikzay A, Ouyang X, Surguladze D, Fleming J, Mitelman S, Camara M, Finnerty B, Doody J, Chekler EL, Kussie P, Tonra JR.

Transl Oncol. 2010 Oct 1;3(5):318-25.

8.

Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.

Youssoufian H, Rowinsky EK, Tonra J, Li Y.

Cancer. 2010 Feb 15;116(4 Suppl):1013-7. doi: 10.1002/cncr.24787.

9.
10.

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

Surguladze D, Deevi D, Claros N, Corcoran E, Wang S, Plym MJ, Wu Y, Doody J, Mauro DJ, Witte L, Busam KJ, Pytowski B, Rodeck U, Tonra JR.

Cancer Res. 2009 Jul 15;69(14):5643-7. doi: 10.1158/0008-5472.CAN-09-0487. Epub 2009 Jul 7.

11.

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

Tonra JR, Corcoran E, Deevi DS, Steiner P, Kearney J, Li H, Ludwig DL, Zhu Z, Witte L, Surguladze D, Hicklin DJ.

Anticancer Res. 2009 Jun;29(6):1999-2007.

12.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Bassi R, Persaud K, Rohoza-Asandi A, Balderes P, Loizos N, Ludwig DL, Tonra J, Witte L, Zhu Z.

Neoplasia. 2009 Jun;11(6):594-604.

13.

In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.

Tonra JR, Prewett M, Corcoran E, Hicklin DJ, Zhu Z.

Methods Mol Biol. 2009;525:545-57, xv. doi: 10.1007/978-1-59745-554-1_30.

PMID:
19252838
14.

Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

Duncton MA, Piatnitski Chekler EL, Katoch-Rouse R, Sherman D, Wong WC, Smith LM 2nd, Kawakami JK, Kiselyov AS, Milligan DL, Balagtas C, Hadari YR, Wang Y, Patel SN, Rolster RL, Tonra JR, Surguladze D, Mitelman S, Kussie P, Bohlen P, Doody JF.

Bioorg Med Chem. 2009 Jan 15;17(2):731-40. doi: 10.1016/j.bmc.2008.11.049. Epub 2008 Nov 24.

PMID:
19101155
15.

Functional significance of VEGFR-2 on ovarian cancer cells.

Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK.

Int J Cancer. 2009 Mar 1;124(5):1045-53. doi: 10.1002/ijc.24028.

16.

Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.

Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, Tonra JR.

Clin Cancer Res. 2007 Dec 15;13(24):7432-40.

17.

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.

Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. Review.

18.

An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.

Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, Jimenez X, Iacolina M, Bassi R, Zhou K, Balderes P, Mangalampalli VR, Loizos N, Ludwig DL, Zhu Z.

Biochem Biophys Res Commun. 2007 Jun 15;357(4):1142-7. Epub 2007 Apr 19.

PMID:
17462601
19.

Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.

Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ.

Clin Cancer Res. 2007 Mar 1;13(5):1540-51.

20.

Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.

Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K.

Cancer Res. 2007 Jan 15;67(2):593-9.

21.

Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.

Tonra JR, Hicklin DJ.

Immunol Invest. 2007;36(1):3-23. Review.

PMID:
17190647
22.

Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys.

Sun HD, Malabunga M, Tonra JR, DiRenzo R, Carrick FE, Zheng H, Berthoud HR, McGuinness OP, Shen J, Bohlen P, Leibel RL, Kussie P.

Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E964-76. Epub 2006 Nov 28.

23.

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.

Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ.

Clin Cancer Res. 2006 Nov 1;12(21):6573-84.

24.

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.

Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, Hicklin DJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2197-207.

25.

1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors.

Pan W, Miao HQ, Xu YJ, Navarro EC, Tonra JR, Corcoran E, Lahiji A, Kussie P, Kiselyov AS, Wong WC, Liu H.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):409-12. Epub 2005 Oct 21.

PMID:
16246560
26.

N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors.

Xu YJ, Miao HQ, Pan W, Navarro EC, Tonra JR, Mitelman S, Camara MM, Deevi DS, Kiselyov AS, Kussie P, Wong WC, Liu H.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):404-8. Epub 2005 Oct 21.

PMID:
16246551
27.

Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Kussie P.

Mol Cancer Ther. 2005 Mar;4(3):369-79.

28.

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9.

30.

Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a combinatorial phage display library.

Qian MD, Villeval JL, Xiong X, Jandrot-Perrus M, Nagashima K, Tonra J, McDonald K, Goodearl A, Gill D.

Hum Antibodies. 2002;11(3):97-105.

PMID:
12454370
31.

Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury.

Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y.

J Neuroimmunol. 2002 Apr;125(1-2):59-65.

PMID:
11960641
32.

Reduced Ia-afferent-mediated Hoffman reflex in streptozotocin-induced diabetic rats.

Tonra JR, Cliffer KD, Carson SR, Lindsay RM, Bodine SC, DiStefano PS.

Exp Neurol. 2001 Nov;172(1):220-7.

PMID:
11681854
33.

The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE.

Rottman JB, Smith T, Tonra JR, Ganley K, Bloom T, Silva R, Pierce B, Gutierrez-Ramos JC, Ozkaynak E, Coyle AJ.

Nat Immunol. 2001 Jul;2(7):605-11.

PMID:
11429544
34.

Comparison of the timing of acute blood-brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis.

Tonra JR, Reiseter BS, Kolbeck R, Nagashima K, Robertson R, Keyt B, Lindsay RM.

J Comp Neurol. 2001 Jan 29;430(1):131-44.

PMID:
11135250
36.
37.

Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice.

Tonra JR, Ono M, Liu X, Garcia K, Jackson C, Yancopoulos GD, Wiegand SJ, Wong V.

Diabetes. 1999 Mar;48(3):588-94.

PMID:
10078561
38.

Neuronal injury increases retrograde axonal transport of the neurotrophins to spinal sensory neurons and motor neurons via multiple receptor mechanisms.

Curtis R, Tonra JR, Stark JL, Adryan KM, Park JS, Cliffer KD, Lindsay RM, DiStefano PS.

Mol Cell Neurosci. 1998 Oct;12(3):105-18.

PMID:
9790733
39.

Consistent repeated M- and H-Wave recording in the hind limb of rats.

Cliffer KD, Tonra JR, Carson SR, Radley HE, Cavnor C, Lindsay RM, Bodine SC, DiStefano PS.

Muscle Nerve. 1998 Nov;21(11):1405-13.

PMID:
9771663
40.

Axotomy upregulates the anterograde transport and expression of brain-derived neurotrophic factor by sensory neurons.

Tonra JR, Curtis R, Wong V, Cliffer KD, Park JS, Timmes A, Nguyen T, Lindsay RM, Acheson A, DiStefano PS.

J Neurosci. 1998 Jun 1;18(11):4374-83.

41.

Effects of postnatal anti-NGF on the development of CGRP-IR neurons in the dorsal root ganglion.

Tonra JR, Mendell LM.

J Comp Neurol. 1998 Mar 23;392(4):489-98.

PMID:
9514512
42.

Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat.

Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, DiStefano PS.

Ann Neurol. 1998 Jan;43(1):46-55.

PMID:
9450768
43.

Rabbit IgG distribution in skin, spinal cord and DRG following systemic injection in rat.

Tonra JR, Mendell LM.

J Neuroimmunol. 1997 Dec;80(1-2):97-105.

PMID:
9413264

Supplemental Content

Support Center